logo
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, has licensed its real-world data to enhance clinical trial design and analytics.
Through this agreement, Recursion will integrate HealthVerity de-identified data for over 340M covered lives within the US into its advanced data science and machine learning platforms, the Recursion OS, allowing for deeper insights into patient populations, enhanced trial design and feasibility assessments, as well as clinical operations workflows. By leveraging these high-quality, linked data assets, Recursion seeks to industrialize clinical development, reduce costs, and accelerate the development of novel therapeutics.
'Our partnership with Recursion underscores the transformative potential of real-world data in driving smarter clinical trials,' said Andrew Kress, CEO of HealthVerity. 'By providing seamless access to the industry's most comprehensive and interoperable real-world data, we empower innovators like Recursion to make data-driven decisions that streamline clinical development.'
Recursion's proprietary AI-driven approach relies on integrating diverse datasets and AI/ML models to identify novel insights into human biology and molecule design. The incorporation of real-world data from HealthVerity Marketplace will further strengthen Recursion's ability to predict patient responses, refine study designs, and ensure clinical trial sites are positioned to meet enrollment goals.
'With the majority of the industry's time and resources focused on clinical trials, we see a significant opportunity to transform how clinical development is designed and executed,' said Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer at Recursion. 'By integrating privacy-compliant real-world data from HealthVerity into Recursion OS, we are advancing our mission to optimize trial design through in silico simulations, accelerate recruitment through a patient-centric approach that includes underserved populations, and generate stronger evidence to inform development and regulatory decisions. By doing so, we are not only streamlining clinical development but also ensuring that we bring more impactful, life-changing treatments to patients faster and more efficiently'
The HealthVerity approach to real-world data acquisition and governance ensures compliance with HIPAA and other regulatory frameworks while maintaining the highest standards of patient privacy. By combining data from the nation's largest healthcare data ecosystem, HealthVerity enables precise patient journey insights, supporting clinical development, regulatory submissions, and post-market studies.
For more information, visit www.healthverity.com.
About HealthVerity
HealthVerity is the leader in privacy-protected real-world data exchange, transforming how healthcare and life sciences organizations connect and analyze disparate patient data. By enabling access to the industry's largest RWD ecosystem, HealthVerity supports critical applications in clinical development, commercial strategy, and regulatory decision-making.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, and chemistry to advance the future of medicine.
Media Contact:
HealthVerity
[email protected]
Recursion
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/healthverity-partners-with-recursion-to-enhance-clinical-trial-analytics-with-real-world-data-302429759.html
SOURCE HealthVerity, Inc.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Canaccord Raises Zeta Global (ZETA)Price Target on Strong Q2 and Expanding AI Adoption
Canaccord Raises Zeta Global (ZETA)Price Target on Strong Q2 and Expanding AI Adoption

Yahoo

time29 minutes ago

  • Yahoo

Canaccord Raises Zeta Global (ZETA)Price Target on Strong Q2 and Expanding AI Adoption

Zeta Global Holdings Corp. (NASDAQ:ZETA) is one of the Zeta Global Holdings Corp. (NASDAQ:ZETA) is one of the best midcap AI stocks to buy right now. On August 6, 2025, Canaccord Genuity maintained its 'Buy' rating on Zeta Global and raised the price target from $26 to $28 on the back of a strong second quarter. Analyst David Hynes emphasized confidence in Zeta's OneZeta platform adoption and AI-aligned 'Zeta Answers' product, citing these as key drivers for expanding engagement. Source: pixabay Despite competitive pressures, Canaccord highlighted Zeta's growth momentum and execution, including revenue growth, EBITDA gains, and accelerating free cash flow. The firm's message was clear: business strength and AI innovation justify an elevated outlook. Zeta Global is a New York–based marketing technology company delivering an omnichannel, AI-enhanced customer acquisition and engagement suite. Its Zeta Marketing Platform (ZMP) uses vast identity and behavioral datasets to enable predictive, data-driven marketing, and it's gaining traction across enterprise clients. While we acknowledge the potential of ZETA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and .

Citigroup Slashes Confluent (CFLT) Price Target Amid Cloud Optimization Headwinds
Citigroup Slashes Confluent (CFLT) Price Target Amid Cloud Optimization Headwinds

Yahoo

time29 minutes ago

  • Yahoo

Citigroup Slashes Confluent (CFLT) Price Target Amid Cloud Optimization Headwinds

Confluent, Inc. (NASDAQ:CFLT) is one of the Confluent, Inc. (NASDAQ:CFLT) is one of the best midcap AI stocks to buy right now. On August 4, 2025, Citigroup maintained its Neutral rating on Confluent but sharply lowered its price target from $30 to $20, signaling a more cautious stance on the company's near-term growth trajectory. Analyst Tyler Radke cited ongoing cloud optimization trends among Confluent's largest customers, which are expected to weigh on the company's cloud revenue growth well into the first half of 2026. Despite the downgrade, the report acknowledged Confluent's position as a leader in real-time data streaming and event-driven architecture. However, with macro pressures prompting clients to rein in cloud spend and elongate deal cycles, Citigroup opted to stay on the sidelines until demand signals improve. The lowered price target reflects a tempered outlook on both consumption-based revenue and the pace of enterprise expansion over the next few quarters. Copyright: nanantachoke / 123RF Stock Photo Confluent is a data infrastructure company based in California. It provides a cloud-native platform built around Apache Kafka, enabling organizations to stream, process, and react to data in real time. While we acknowledge the potential of CFLT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

There's A Lot To Like About Applied Materials' (NASDAQ:AMAT) Upcoming US$0.46 Dividend
There's A Lot To Like About Applied Materials' (NASDAQ:AMAT) Upcoming US$0.46 Dividend

Yahoo

time35 minutes ago

  • Yahoo

There's A Lot To Like About Applied Materials' (NASDAQ:AMAT) Upcoming US$0.46 Dividend

Applied Materials, Inc. (NASDAQ:AMAT) stock is about to trade ex-dividend in 4 days. The ex-dividend date occurs one day before the record date, which is the day on which shareholders need to be on the company's books in order to receive a dividend. The ex-dividend date is an important date to be aware of as any purchase of the stock made on or after this date might mean a late settlement that doesn't show on the record date. Therefore, if you purchase Applied Materials' shares on or after the 21st of August, you won't be eligible to receive the dividend, when it is paid on the 11th of September. The company's next dividend payment will be US$0.46 per share. Last year, in total, the company distributed US$1.84 to shareholders. Based on the last year's worth of payments, Applied Materials stock has a trailing yield of around 1.1% on the current share price of US$161.755. If you buy this business for its dividend, you should have an idea of whether Applied Materials's dividend is reliable and sustainable. That's why we should always check whether the dividend payments appear sustainable, and if the company is growing. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. If a company pays out more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. Applied Materials has a low and conservative payout ratio of just 20% of its income after tax. Yet cash flows are even more important than profits for assessing a dividend, so we need to see if the company generated enough cash to pay its distribution. The good news is it paid out just 23% of its free cash flow in the last year. It's positive to see that Applied Materials's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut. Check out our latest analysis for Applied Materials Click here to see the company's payout ratio, plus analyst estimates of its future dividends. Have Earnings And Dividends Been Growing? Stocks in companies that generate sustainable earnings growth often make the best dividend prospects, as it is easier to lift the dividend when earnings are rising. Investors love dividends, so if earnings fall and the dividend is reduced, expect a stock to be sold off heavily at the same time. That's why it's comforting to see Applied Materials's earnings have been skyrocketing, up 24% per annum for the past five years. Applied Materials earnings per share have been sprinting ahead like the Road Runner at a track and field day; scarcely stopping even for a cheeky "beep-beep". We also like that it is reinvesting most of its profits in its business.' Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. Applied Materials has delivered an average of 16% per year annual increase in its dividend, based on the past 10 years of dividend payments. It's exciting to see that both earnings and dividends per share have grown rapidly over the past few years. Final Takeaway Has Applied Materials got what it takes to maintain its dividend payments? We love that Applied Materials is growing earnings per share while simultaneously paying out a low percentage of both its earnings and cash flow. These characteristics suggest the company is reinvesting in growing its business, while the conservative payout ratio also implies a reduced risk of the dividend being cut in the future. Applied Materials looks solid on this analysis overall, and we'd definitely consider investigating it more closely. Wondering what the future holds for Applied Materials? See what the 32 analysts we track are forecasting, with this visualisation of its historical and future estimated earnings and cash flow A common investing mistake is buying the first interesting stock you see. Here you can find a full list of high-yield dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store